|Awarded On||August 19, 2020|
|Title||Immune Checkpoint Regulation by the Integrated Stress Response Pathway in Lung Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Kathryn O'Donnell|
|Cancer Sites||Lung and Bronchus|
Lung cancer cells have developed strategies to become invisible to the immune system, which would otherwise recognize and eliminate the tumor. Recent studies have shown that one of the most important immune evasion mechanisms is the activation of a protein on the surface of lung cancer cells called PD-L1, for Programmed Death Ligand 1. PD-L1 binds to PD-1 on the surface of immune cells, sending a signal to shut off the immune response. Immunotherapy is a cancer treatment strategy in which the mechanisms through which tumor cells block the immune system are shut off, triggering anti-tumor immune reactions. Clinical trials using immunotherapy drugs that block the binding of the PD-1 receptor t...